StockpollyBeta
Get App
Popularity #1,553
DNLI · NASDAQ · Biotechnology

Denali Therapeutics (DNLI)

Develops brain-penetrating therapies and commercializes AVLAYAH for Hunter syndrome.

$20.62
vs last close−0.98 (−4.56%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue100000000004
Cost of revenue000000000330
Gross profit100000000−3−34
115133118117123130146135137134135134
Research & development9010810791981001161031029810497
252525252530293235373136
General & administrative2525252525302932350036
Other expenses00−15000000001
Operating income−114−133−118−117−123−130−146−135−137−137−137−131
141316181615131111993
Interest income141316181615131111990
Other non-operating income0−1315−18−16−15−13−11−11−9−9−3
Income before tax−99−119−102−99−107−115−133−124−127−128−128−128
Income tax expense000000000000
Net income from continuing operations−99−119−102−99−107−115−133−124−127−129−128−128
Net income−99−119−102−99−107−115−133−124−127−129−128−128
EPS, basic−$0.72−$0.86−$0.68−$0.59−$0.63−$0.67−$0.78−$0.72−$0.74−$0.73−$0.69−$0.68
EPS, diluted−$0.72−$0.86−$0.68−$0.59−$0.63−$0.67−$0.78−$0.72−$0.74−$0.73−$0.69−$0.68
Weighted average shares, basic138138149169169170171171172175187187
Weighted average shares, diluted138138149169169170171171172175187187
EBITDA−112−117−130−97−105−112−130−120−123−125−126−124
Depreciation & amortization222223344434
EBIT−114−119−132−99−107−115−133−124−127−128−128−128